HONG KONG – New RNA-based switching biotechnology that detects and sorts cells derived from induced human pluripotent (iPS) cells using microRNAs (miRNAs) will enable production of purer cell populations with potentially better therapeutic outcomes, a study by Japanese researchers at the Center for iPS Cell Research and Application (CiRA) at Kyoto University has found. Read More
HONG KONG – Biotech and medtech companies operating in China now have to pay more attention to the cost of regulatory approvals after the national regulator drastically raised registration application fees for both clinical trials and marketing approvals. Read More
HONG KONG – In a move that sent its stock down more than 3 percent Tuesday, Hong Kong-listed Chinese pharmaceutical company Luye Pharma Group (HK:2186) terminated a billion-dollar acquisition deal. Read More
R-Tech Ueno Ltd., of Tokyo, reported that the phase I single-dose study for its anti-inflammatory and immunomodulatory agent, RTU-1096, has been completed, confirming safety and tolerability of the drug up to the highest dose. Read More
